The book focuses on drug discovery for psychiatric and neurological diseases, which is in a phase of explosive growth. Chapters are divided into two major sections. The first section presents fundamentals of drug discovery, highlighting the modern techniques and approaches of drug discovery in biotech and pharmaceutical companies. Specific aspects of brain diseases, such penetration of the blood-brain barrier, are addressed. The author pays particular attention to clinical proof-of-concept research. Discussion of drug discovery for the major nervous system diseases represents the second section of the book. Each chapter looks at a particular class of disease, beginning with a summary of current understanding of disease mechanism and treatment, followed by thorough discussion of novel targets and emerging drugs.
Buy Drug Discovery for Nervous System Diseases book by Franz F. Hefti from Australia's Online Independent Bookstore, Boomerang Books.
(255mm x 180mm x 18mm)
John Wiley & Sons Inc
Publisher: John Wiley and Sons Ltd
Country of Publication:
Author Biography - Franz F. Hefti
Franz F. Hefti, PhD, held academic positions between 1985 and 1995, first as Associate Professor at the University of Miami, Florida, than as Professor with endowed chair at the University of Southern California in Los Angeles. He conducted pioneering research in the area of neurotrophic factors by demonstrating that these proteins can rescue dying nerve cells in the adult brain. He has served as Director of Neuroscience Research at Genentech Inc., pursuing industrial applications of his research on neurotrophic factors, leading to phase III trials with nerve growth factor. Since 1995 his activities have been dedicated to the discovery of novel drugs for neurological and psychiatric diseases in the pharmaceutical industry. From 1995 to 2001 he was Vice President at Merck Research Laboratories and Director of The Neuroscience Research Centre of Merck Sharp & Dohme. He later served as Senior Vice President of Neuroscience Research at Merck & Co.